Author Archives: Darren Marchal

Stocks Have Never Been More Expensive Based On Long-Term Growth F

As the S&P 500 pushes towards Goldman Sachs’ 2,100 year end target (for 2015!!) today, we thought it worth considering just how much awesomeness has been pulled forward, priced-in, exuberantly-chased. As the following charts show, based on bottom-up long-term-growth expectations, S&P forward P/E valuations have never been higher. But that’s not all… The current Forward P/E…

Will Stryker Finally Bid On Smith & Nephew This New Year?

Rumors hinting at the takeover of U.K.-based Smith & Nephew plc (SNN –Snapshot Report) by its U.S. rival Stryker Corporation (SYK – Analyst Report), dating back to May 2014, resurfaced this week. According to a latest Bloomberg report, a Stryker move for Smith & Nephew could come in as early as the next few weeks. The renewed takeover speculation brought an early…

EC Connecting

There is no question that falling oil prices are good for a USA-style consumer-driven economy. Falling oil prices put more money into the hands of the consumer — and it is appearing the consumer is now spending more in this holiday season. Already, falling oil prices are migrating into the supply chain reducing costs of…

Top Buyouts To Watch For In 2015

2014 has been the best year for M&A since the financial crisis, but we think 2015 could be even better. The market is flush with easy financing and cheap debt which has large companies looking to acquisitions for growth. Here are our top candidates to be bought out in this new year. There’s a perfect…

Does Biotech Bearishness Lie Ahead?

The biotech sector experienced a big shock on Monday, December 22, just one trading day after new record intraday and closing highs had been reached by the four most-heavily-traded biotech ETFs:  the iShares Nasdaq Biotechnology Index ETF (IBB), the SPDR S&P Biotech Index ETF (XBI), the Market Vectors Biotech ETF (BBH) and the First Trust…